



GRAPHHDAN

scientific

DESIGN

2017

Graphical abstracts & scientific posters

Technical Drawing & Book Covers

scientific animations



GRAPHDAN

با سلام خدمت شما استاد/محقق گرامی

مجموعه پیش روی شما بخشی از عملکرد گروه تخصصی گرافدان در سال های اخیر است. گرافدان گروهی دانش بنیان در زمینه بهبود کیفیت گرافیکی پروژه های علمی است.

این گروه زیر نظر اینجانب مهدی صفدریان دانش آموخته دکتری تخصصی نانوتکنولوژی دارویی اداره می شود. در حال حاضر در این گروه فارغ التحصیلانی از رشته های شیمی، زیست شاسی، الکترونیک، فیزیک و ... مشغول به فعالیت هستند.

عمده فعالیت های گروه گرافدان در زمینه طراحی موضوعی و تخصصی انواع پوستر علمی و پوستر همایش ها و نیز طراحی تصاویر گرافیکال ابترکت (GRAPHICAL ABSTRACT) یا چکیده تصویری برای مقاله های علمی است. امیدوارم من و همکارانم در پروژه های علمی پیش روی شما بتوانیم همکاری مفیدی با شما داشته باشیم.




scientific

DESIGN
2017

Graphical abstracts & scientific posters

Technical Drawing & Book Covers

scientific animations



Journal of Chromatography A

Impact Factor: 4.2

Corresponding author: Z. Ramezani

Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.

1396

Graphical abstract 1




@graphdanir



09013767627



www.Graphdan.ir




Carbohydrate Polymers

Impact Factor: 4.811

Corresponding author: Dr M. Hashemi
Bu-Ali Sina University, Hamedan, Iran

1396

Graphical abstract 2



Analytical Methods

Impact Factor: 1.9

Corresponding author: Dr K. Ghanemi

Khorramshahr University of Marine Science and Technology, Iran

1396

Graphical abstract 3




@graphdanir



09013767627



www.Graphdan.ir



Analytica Chimica Acta

Impact Factor: 4.950

Corresponding author: Dr. P. Hashemi

Lorestan University, Khoramabad, Iran

1396

Graphical abstract 4




@graphdanir



09013767627



www.Graphdan.ir



Journal of Photochemistry and Photobiology A: Chemistry

Impact Factor: 2.625

Corresponding author: Dr. H. Faghihian
Shahreza Branch, Shahreza, Iran

1396

Graphical abstract 5




@graphdanir



09013767627



www.Graphdan.ir



Colloids and Surfaces A: Physicochemical and Engineering

Impact Factor: 2.714

Corresponding author: Dr. Z. Ramezani

Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran

1396

Graphical abstract 6




@graphdanir



09013767627



www.Graphdan.ir




Analytica Chimica Acta

Impact Factor: 4.950

Corresponding author: Dr. P. Hashemi

Lorestan University, Khoramabad, Iran



Desalination

Impact Factor: 5.527

Corresponding author: Dr. Y. Mansourpanah
Lorestan University, Khoramabad, Iran

1396

Graphical abstract 8



14th International Congress of
Multiple Sclerosis



Cross-Cultural Evaluation of Psychometric Properties of the High-Level Language Test (BeSS) in Persian Speakers

Majid Soltani^{*}, Parvane Rahimifar^{*}, Negin Moradi^{*}, Seyed Mahmood Latifi^{},
Nadereh Madjdinasab^{***}**

^{*} Musculoskeletal Rehabilitation Research Center, Dept. of Speech Therapy, Alvin Jundishapur University of Medical Sciences, Ahvaz, Iran


^{**} Health Research Institute, Diabetes Research Center, Alvin Jundishapur University of Medical Sciences, Ahvaz, Iran.

^{***} Dept. of Neurology, Golestan Hospital, Jundishapur Medical University, Ahvaz, Iran.

Corresponding author: majidsoltani@gmail.com

Introduction

Patients with progressive neurological diseases such as Multiple Sclerosis (MS) experience speech production impairment as well as language disorders. One of the language impairments observed among patients is high-level language skills impairment. Language problems cause defects in individuals' quality of life. Therefore, in order to prevent decreased quality of life, diagnosis of language disorders is of high importance in the early stages of the disorder. To evaluate language disorders in progressive neurological patients, some certain tests have been used which lacked sufficient sensitivity and complexity



to determine the features of language skills precisely. Therefore, researchers are making tests with sufficient accuracy and complexity to investigate high-level language disorders. One of these tests is called Bedomning av Subtila Spraksforningar (BeSS). Due to the lack of accurate measurement tools in clinical environments in Iran, this can cause inappropriate treatment programs to be implemented which may in turn affect individuals' quality of life negatively. Therefore, this study aimed to investigate Cross-Cultural Evaluation of Psychometric Properties of the High-Level Language Test BeSS in Persian Speakers.

Methods

This study was conducted on 20 MS patients affiliated to Khuzestan MS association as well as 20 healthy individuals. After translating BeSS to Persian, its content validity was determined based on 10 experts working in the same field. Also, the reliability of the test was determined using techniques such as test-retest method, Cronbach's alpha and clinical validity.

Results

The content validity ratio (CVR) was higher than 0.82 for every subtest and content validity index (CVI) was between 0.1 and 0.8 for all subtests. Cronbach's alpha coefficient for the test and subtests was between 0.7 and 0.94 and repeatability coefficient (ICC) was between 0.8 and 0.96. Clinical validity results showed significant difference between means of patients' scores and healthy subjects scores ($p = 0.0001$).

Conclusion


The Persian version of BeSS seems to benefit from high reliability and validity values. Thus, speech therapists can use this test to examine high-level language disorders in MS patients with relative certainty regarding its reliability and validity.

Key words

BeSS, high-level language skills, MS

Reference

1. Barwood C and Murdoch BE. Language abilities of patients with primary progressive multiple sclerosis: A preliminary group and case investigation. *International journal of speech-language pathology*. 2013.
2. Louhevaara K, Brunneberg K, Hartzelius I and Ahlborn E. Assessing high-level language in individuals with multiple sclerosis: a pilot study. *Clinical linguistics & phonetics*. 2000; 14: 329-48.
3. Lethbrun JB and Murdoch BE. Performance of subjects with multiple sclerosis on tests of high-level language. *Aphasiology*. 1997; 11: 38-57.
4. Crossen B. Assessment of subtle language deficits in neuropsychological batteries: Strategies and implications. *Ecological validity of neuropsychological testing*. Delray, FL: GR Press/3M Lucie press, Inc. 1996.



Zahra Ramezani^a, Mehdi Safdarian^b

^aNeurochemistry Research Center, Alborz Jondishapur University of Medical Sciences, Alborz, Iran
^bMedicinal Chemistry Department, Faculty of Pharmacy, Alborz Jondishapur University of Medical Sciences, Alborz, Iran
 E-mail: z.ramezani@ajums.ac.ir

1. Introduction:

To the best of our knowledge, techniques available for monitoring perphenazine and other neuroleptics are gas chromatography (GC) and high-performance liquid chromatography (HPLC) [1]. complex matrix of biological samples low Level of drugs in urine makes direct measurements difficult and clean up and/or pre-concentration procedure is required prior to determination. High-performance thin-layer chromatography (HPTLC) is an alternative technique to HPLC [2]. In this study, a new, simple, accurate, and precise normal phase HPTLC method coupled to dispersive solid phase extraction based on magnetic molecularly imprinted polymer (MMIP) has been established for analysis of PPZ in human urine sample. Finally, the results obtain from HPTLC method are compared with those of HPLC as standard method reported by United State Pharmacopeia method for PPZ assay.

2. Results and discussion

HPLC determination of PPZ

Fig. 1. HPLC chromatograms obtained for PPZ extracted from urine by the proposed method A) before and B) after applying with 6.3 ppm C) 1.2 ppm and D) 2 ppm PPZ, experimental condition amount of MMIP, 5 mg, sample volume, 5 µL, pH, 6, contact time, 1 min.

Fig. 2. Method calibration curve for perphenazine by HPLC.

HPTLC determination of PPZ

Fig. 3. HPTLC chromatograms obtained for PPZ extracted from urine by the proposed method.

Fig. 4. Method calibration curve for perphenazine by HPTLC.

Diagram illustrating the structure of the magnetic molecularly imprinted polymer (MMIP) used for preconcentration. The structure consists of a magnetic core, a polymer shell, and a MAA shell.

Table 1

Comparing validity for PPZ determination in urine by HPLC and HPTLC methods


Parameter	HPLC	HPTLC
Linear range (µg/L)	0.001-0.010	0.001-0.010
Detection limit (µg/L)	0.001	0.001
Quantification limit (µg/L)	0.002	0.002
LOD	0.001	0.001
Mean recovery (%) (n=3)	100	100
RSD (%) (n=3)	1.5	1.5

Table 2

Analytical results for the determination of PPZ in clinical samples by the proposed method, under the optimized conditions (mean ± S.D., n = 3).

Sample	Added (µg/L)	Found (µg/L)	Recovery (%)	S.D. (%)
Sample 1	0.01	0.010 ± 0.001	100	1.5
	0.02	0.020 ± 0.002	100	1.5
	0.05	0.050 ± 0.005	100	1.5
Sample 2	0.01	0.010 ± 0.001	100	1.5
	0.02	0.020 ± 0.002	100	1.5
	0.05	0.050 ± 0.005	100	1.5
Sample 3	0.01	0.010 ± 0.001	100	1.5
	0.02	0.020 ± 0.002	100	1.5
	0.05	0.050 ± 0.005	100	1.5


Fig. 5. Determination of perphenazine



Protective effect of Diosmin against cisplatin-induced kidney injury in rats

Roza Habibi¹, Mohamad Javad Khodayar^{1,2}, Masoud Mahdavi¹, Esrafil Mansouri¹

¹ Department of Pharmacology and Toxicology, School of Pharmacy, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran
² Toxicology Research Center, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran
³ Cellular and Molecular Research Center, Department of Anatomical Sciences, Faculty of Medicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran



Introduction and background


Cisplatin (Cis) is one of the most potent chemotherapeutic antitumor drugs, however there is a concern due to its toxic side effects especially on renal tissue. Diosmin (Do) a citrus flavonoid which shown anti-inflammatory, antimutagenic and antioxidative properties resulting from its structure. This study was undertaken to investigate the preventive effect of Do in nephrotoxicity induced by Cis in male rats.


Methods


In this experimental study, Wistar male rats were divided randomly into six groups of six in each group. The control group received saline; Cis treated group; Cis+Do treated group and Do treated group. Rats were pretreated with Do (25, 50, 100 mg/kg/day, ip) for 8 consecutive days and Cis (10 mg/kg BW, ip) was administrated on the 6th day. Blood samples were collected to determine serum creatinine (Cr), urea, uric acid and blood urea nitrogen (BUN) levels. Malondialdehyde (MDA), glutathione (GSH), and antioxidant enzymes activity catalase (CAT), superoxide dismutase (SOD) and Glutathione peroxidase (GPx) activity were assayed in left renal tissue. The right kidney was maintained in 10% formalin for Hematoxylin and Eosin (H&E) staining and histological examination.

Results

Results showed a significant increase in the levels of MDA, Cr and BUN, and decrease of GSH, CAT, GPx and SOD activity by Cis administration. Pre-treatment with Do Showed reduction in the levels of MDA, Cr and BUN and increase of GSH, CAT, GPx and SOD activity in all doses but the most significant alteration was observed at doses of 100 mg/kg (P<0.05). Additionally the nephroprotective effect of the Do was established by the histological examination of the kidneys.







Histopathological observations (kidney sections stained with Hematoxylin & Eosin, magnification × 100) showing effects of Diosmin on Cisplatin -induced nephrotoxicity changes in rats kidney. (A) Normal, (B) Cisplatin treated group, (C), (D) and (E) are Cisplatin group pre-treated with 25, 50 and 100 mg/kg of Diosmin, respectively. (F) is Diosmin treated group

Conclusion

Our results indicated that Do have produced amelioration in biochemical indices and oxidative stress parameters against Cis-induced nephrotoxicity.

References

1. Kani F, Oskaner OK, Ozdemir-Kumral ZK, Abroglu K, Ertem I, Cakir Z, et al. Protective effect of ferulic acid on cisplatin induced nephrotoxicity in rats. *Emmon Toxicol Pharmacol*. 2017;54:105-13.
2. Wajner W, Kaczmarek-Szaflik I, Fich M. Diosmin Ameliorates The Effects Of Oxidative Stress In Lenses Of Streptozotocin-Induced Type 1 Diabetic Rats. *Pharmacol Res*. 2017.
3. Simenoglu O, Yener AN, Kizil S, Mili A, Aksoygun FB. The Protective effects of quinine in cyclophosphamide induced nephrotoxicity and vertigo in rats. *Urology*. 2012;80(6):1392. e1- e6.

Corresponding author Email : jkhodayar@yahoo.com

Keywords
Nephrotoxicity
Diosmin
Cisplatin
Rats



Study the effect of methanolic extract of Persian shallot against lipid peroxidation in liver, kidney, brain and its antioxidant capacity in rat serum

Paria Javam¹, Amir Shahpoosh², Mohamadreza Momeni Ghomi³, Alireza Malayeri¹

¹ Pharmacy Student of Alireza Jandaghpour University of Medical Sciences
² Medicinal Plants Research Center and Department of Pharmacognosy Faculty of Pharmacy, Alireza Jandaghpour University of Medical Sciences
³ Pharmacology Research Center and Department of Pharmacology Faculty of Pharmacy, Alireza Jandaghpour University of Medical Sciences



Introduction and background


Free radicals can cause tissue damage and diseases such as cancer, arthritis, atherosclerosis, diabetes, etc. So harmless antioxidants can be used to prevent diseases related to free radicals. Some plants are important sources of harmless antioxidants compound with different structures. *Allium hirtifolium* which is used as edible and also recognized plant in Iran traditional medicine is useful for therapeutic uses such as cardiovascular and atherosclerosis diseases.

Crude extract of *Allium hirtifolium* was prepared with maceration method. Normal male rats were fed with dose of 100 and 1000 mg/kg of crude extract; vitamin C was used as positive control. Using thiobarbituric acid (TBA) method, malondialdehyde concentration was determined to be a marker of lipid peroxidation of brain, kidney, heart, liver and pulmonary tissues. Antioxidative capacity of the serum was evaluated by DPPH, FRAP and ABTS assays.

Methods

Results

Results indicate that compared to the control group, extract of 100 mg/kg could reduce the lipid peroxidation of normal rats' brain, kidney, heart, liver and pulmonary tissues but with the dose of 1000 mg/kg lipid peroxidation increased and became almost identical to the control group. The dose of 100 mg/kg, in comparison with the dose of 1000 mg/kg, could increase the antioxidative capacity in DPPH and ABTS assays but in FRAP assay, the 1000 mg/kg dose was more powerful.



Results showed that *Allium hirtifolium* extract (100 mg/kg dose) can reduce lipid peroxidation in different tissues and increase the antioxidative capacity of the serum but a reversal result can be achieved by increasing the dose.

Discussion and Conclusion

Keywords

Allium hirtifolium
Lipid peroxidation
Antioxidant
DPPH
FRAP
ABTS

References

- Densov ET, Afanasov IB. Oxidation and Antioxidants in organic chemistry and biology. Boca Raton: CRC Press, 2005; 905 - 940.
- Zhang CH, Malhorta SV. Increased paraoxon detection by acetylcholinesterase inactivation with ionic liquid additives. *Talanta*. 2005;67:565-3
- Solehi M, Jafari M, Asgari AR, Saleh Mogadam M, Salimian M, Abarnejat M, Haghgholizadeh M. Response of brain antioxidant defense system to acute doses of paraoxon in male rats. *JAUMS*. 2009; 12: 22-23.



Corresponding author: bond
pariajavam@gmail.com



Review of effect of bupropion on attenuates methamphetamine self-administration in adult male rat



Fatemeh hajipour¹, Sina hoseini zare¹, Alireza malaiey^{2,3}

¹Student research committee, school of pharmacy, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.

²Pharmacology research center, school of pharmacy, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.

³Department of pharmacology, school of pharmacy, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.

Introduction

Methamphetamine is a highly potent, addictive drug that is widely abused in many countries around the world. Methamphetamine produces a general state of well-being along with increased wakefulness, talkativeness, and physical activity and decreased appetite. Behavioral treatment programs have had some success in the treatment of methamphetamine addiction, yet many patients continue to relapse after repeatedly seeking treatment. Thus, pharmacotherapeutic treatments for methamphetamine addiction are being evaluated.

Bupropion is an atypical antidepressant with stimulant properties. This drug has been used off-label to treat methamphetamine addicts, thus prompting the need for systematic investigations of its efficacy.

Method and material

male Wistar rats, weighing 200–250 g (8 weeks old) at the start of the experiment. For surgery, rats were anesthetized with 2–3% of isoflurane mixed in oxygen. They were implanted with a silastic catheter (0.3×0.64 mm OD; Dow Corning Co.) into the right external jugular vein under aseptic conditions. After the surgery rats were trained to press a lever of methamphetamine reinforcement (0.05 mg/kg/injection of methamphetamine hydrochloride) in operant boxes under baseline conditions (1h access per day for ten days / 6 h per session for 17 sessions).

When responding stabilized, rats entered the acute testing phase. Each rat was tested with a unique order of vehicle, 10, 30, and 60 mg/kg bupropion. Each solution was administered IP 5 min before placement in the chamber for a regular self-administration session and each test was separated by at least 2 maintenance days of methamphetamine self-administration without drug pretreatment.

Results

bupropion pretreatment appeared to decrease active lever responding. Consistent with the active lever data, rats treated with 60 mg/kg bupropion took significantly fewer total methamphetamine infusions in comparison to the other 2 groups. When Control rats (n=6) (i.e., those pretreated with saline in the previous phase) were given an acute injection of 30 mg/kg bupropion, lever pressing decreased.

Discussion


Several questions remain about bupropion's impact during withdrawal, abstinence, and relapse in a preclinical setting. Research investigating these aspects of addiction will help provide a clearer picture on the effects of bupropion on methamphetamine self-administration in laboratory animals and methamphetamine abuse in humans.

keywords

subject-rated drug effects
physiological drug effects
self-administration
methamphetamine
bupropion

References

1. Reichel CM, Murray JE, Grant KM, Bevins RA. Bupropion Attenuates Methamphetamine Self-Administration in Adult Male Rats. *Drug and alcohol dependence*. 2009 100(1-2): 54-62.
2. Newton, T. F., bupropion reduces methamphetamine-induced subjective effects and cue-induced craving. *Neuropsychopharmacology* 2006 31 1537-1544.
3. Reichel, C. M., Bupropion differentially impacts acquisition of methamphetamine self-administration and sucrose-maintained behavior. *pharmacol biochem behav* 2008 98(3) 463-472.





A new dispersive liquid-liquid microextraction device for cold column solidification and trapping of organic phase



Payman Hashemi,* Mehdi Safdarian, Malihe Naderlo, Ali Reza Ghiasvand
Department of Chemistry, Faculty of Science, Lorestan University, Khoramabad, Iran
E-mail: payman_hashemi@yahoo.com

1. Introduction:

Depending on the nature of the analyte there are many methods for preconcentration, separation and determination [1] such as liquid-phase microextraction [2], single-drop microextraction [3] and dispersive liquid-liquid microextraction (DLLME) [4]. A critical step in all these methods is to separate organic compounds from aqueous phase [1,2]. We have designed a homemade new portable device with the ability of temperature programming to solidify and separate micro volumes of organic solvents from aqueous phase and eliminate the centrifugation step in DLLME method.

2. Apparatus and DLLME-CCT Procedure

A column with 3 mm diameter and 40 mm length was drilled in a block of Plexiglass and filled with glass particles with average diameters of 500 μm .

The column block was sandwiched between a pair of thermal electric coolers (TEC), equipped with two heat sinks and two fans. A temperature sensor was embedded in a hole in the Plexiglass piece.

A controller unit consisted of an interface device with LCD character was assembled and programmed for column temperature controlling. A 3 ml glass syringe was fixed on top of the column. The column temperature could be set with an accuracy of 0.1 $^{\circ}\text{C}$ within a working temperature range of -10

1. The sample (100 μL) was injected into the syringe.
2. The syringe plunger was pushed down to inject the sample into the column.
3. The column (CCT) under the syringe was immersed into the water bath and the column temperature was adjusted to the set value.
4. After organic phase containing the analyte was solidified and trapped on the column.
5. The column temperature was then set to maximum by pressing "Up to start" key.
6. The trapped organic solvent was washed out by 400 μL ethanol and collected into a vial.




Fig. 1. Schematic representation of the main parts of the DLLME-CCT device.



Fig. 2. The temperature program applied to the column for the DLLME-CCT system.

3. Results and discussion:

The system was successfully used for the extraction of curcumin from serum samples. Recoveries higher than 90% and relative a standard deviation of 2.87% was obtained for 5 replicated analysis of curcumin. The detection limit of curcumin determination was calculated to be 28 ng mL⁻¹.



Fig. 3. Influence of volume of ethanol on the extraction recovery (%) of curcumin in the DLLME-CCT system using 10 and 15 $^{\circ}\text{C}$ as the maximum and minimum column temperatures, respectively.




Fig. 4. Influence of aqueous phase volume on the extraction recovery (%) of curcumin in the DLLME-CCT system using 400 μL as the solvent volume.

Table 1. The results obtained for the human serum samples, before and after spiking by 1 ng L⁻¹ curcumin. A CF of 1.14 was applied for the calculations.


Sample no.	Before spike, ng L ⁻¹	After spike, ng L ⁻¹	Recovery, %
1	0.021 ± 0.005	0.017 ± 0.012	80.3
2	0.043 ± 0.011	0.065 ± 0.002	97.8
3	0.088 ± 0.017	0.037 ± 0.046	100.4

The designed CCT device is inexpensive, portable and easily operated and may be adapted to a wide range of organic solvents. The system can be potentially used for both lighter and heavier than water organic solvents. Being a portable device, allows the use of the DLLME-CCT system both in the laboratory and for on-site applications.

References

- [1] M. Rezaei, Y. Yamini, *Journal of Chromatography A*, 1217 (2010) 2342.
- [2] Y. Wang, G. Zhao, *Chinese Journal of Analytical Chemistry*, 38 (2010) 1113.
- [3] Y. He, H. Liu, *Anal. Chem.*, 69 (1997) 4634.
- [4] M. Rezaei, Y. Assadi, *Journal of Chromatography A*, 1116 (2006) 1.






ajums

OP-0048 Postpartum metabolic outcomes in obese or overweight women with gestational diabetes

S. Noubjahi¹, H. Shabbazi², S. Jahanfar³, N. Shabbazi⁴, A. Jahanshahi⁵, R. Cheraghian⁶, N. Ghodrati⁷

¹Social Determinants of Health Research Center - Ahvaz Jondishapur University of Medical Sciences - Ahvaz - Iran.
²Diabetes Research Center - Health Research Institute - Ahvaz Jondishapur University of Medical Sciences - Ahvaz - Iran.
³School of Health Sciences Building 2212 - Room 2239 Central Michigan University - Mount Pleasant MI 48859 - Michigan - USA.
⁴Department of Obstetrics and Gynecology - Fertility Infertility and Perinatology Research Center - Imam Khomeini Hospital - Ahvaz Jondishapur University of Medical Sciences - Ahvaz - Iran.
⁵Diabetes Research Center - Ahvaz Jondishapur University of Medical Sciences - Ahvaz - Iran.
⁶Department of Epidemiology and Biostatistics - Faculty of Health - Ahvaz Jondishapur University of Medical Sciences - Ahvaz - Iran.
⁷Faculty of Pharmacy - Ahvaz Jondishapur University of Medical Sciences - Ahvaz - Iran.



**IDF
Congress
2017**
4-8 December
Paris, France

Background

A history of gestational diabetes mellitus (GDM) is an important predictor of many metabolic disturbances later in life(1,2). Apart from GDM, obesity as a global health concern has not only been associated with higher risk of cardiovascular disease, but also its association with mortality has shown in previous report(3).

Aim

We set out to determine the rate of glucose intolerance and metabolic syndrome at 6-12 weeks postpartum in women with gestational diabetes. Additionally, contributing risk factors and potential differences between obese and overweight women with women with normal body mass index were assessed.

Method

In this ongoing population-based prospective cohort study (LAGAs) 176 women with GDM pregnancy underwent a fasting glucose test, 75-g oral glucose tolerance and fasting lipid tests at 6-12 weeks postpartum in Ahvaz (southwestern of Iran) in 2016.

GDM was defined based on International Association of Diabetes and Pregnancy Study Groups (IADPSG) criteria. Postpartum glucose intolerance was defined according to ADA criteria and metabolic syndrome using 2 sets of criteria, National Cholesterol Education Program Adult Treatment Panel (NCEP ATP III) and International Diabetes Federation (IDF) criteria.





Figure 1. Women who attended for postpartum follow up based on distance from center of Ahvaz (Google Map)

Results

Of 176 women with GDM 71.6% had BMI ≥ 25 before pregnancy (30.1% were obese and 41.3% were overweight). Incidence of glucose intolerance at 6-12 weeks after GDM pregnancy in women with pre-pregnancy excess BMI was 25.4% (28.3% in obese women with GDM vs 23.3% in overweight women). Incidence of progression to glucose intolerance was 14% in women with normal pre-pregnancy body mass index.

Rate of metabolic syndrome at 6-12 weeks postpartum was 23.8% in overweight and obese women with GDM vs 4% in GDM-exposed women with normal pre-pregnancy BMI by NCEP-ATP III criteria and 23.8% in women with overweight and obese women vs 14% in women with normal pre-pregnancy BMI by IDF criteria.

Pre-pregnancy overweight or obesity, (OR 1.89, 95% CI: 1.05-3.38, $P=0.03$) was associated risk factors for the presence of MetS in GDM-exposed women.




Characteristic	Number (n)	Percentage (%)
Study population	176	100
Pre-pregnancy BMI (kg/m ²)		
Normal	108	61.4
Overweight	67	37.9
Obese	1	0.6
Pre-pregnancy BMI (kg/m ²)		
Normal	108	61.4
Overweight	67	37.9
Obese	1	0.6
GDM	176	100
Normal	108	61.4
Overweight	67	37.9
Obese	1	0.6

Variable	Mean (SD)	Median (IQR)	P value
Pre-pregnancy BMI (kg/m ²)	27.8 (4.5)	27.0 (24.0-31.0)	<0.001
Pre-pregnancy BMI (kg/m ²)	27.8 (4.5)	27.0 (24.0-31.0)	<0.001
Pre-pregnancy BMI (kg/m ²)	27.8 (4.5)	27.0 (24.0-31.0)	<0.001
Pre-pregnancy BMI (kg/m ²)	27.8 (4.5)	27.0 (24.0-31.0)	<0.001
Pre-pregnancy BMI (kg/m ²)	27.8 (4.5)	27.0 (24.0-31.0)	<0.001
Pre-pregnancy BMI (kg/m ²)	27.8 (4.5)	27.0 (24.0-31.0)	<0.001
Pre-pregnancy BMI (kg/m ²)	27.8 (4.5)	27.0 (24.0-31.0)	<0.001
Pre-pregnancy BMI (kg/m ²)	27.8 (4.5)	27.0 (24.0-31.0)	<0.001
Pre-pregnancy BMI (kg/m ²)	27.8 (4.5)	27.0 (24.0-31.0)	<0.001
Pre-pregnancy BMI (kg/m ²)	27.8 (4.5)	27.0 (24.0-31.0)	<0.001

Table 1. Mean (SD) of Demographic, Clinical and laboratory characteristics of women with gestational diabetes (diagnosed by IADPSG criteria)

Table 2. Distribution of metabolic syndrome and its components in women with gestational diabetes in accordance with NCEP ATP III and IDF criteria at 6-12 weeks postpartum (n=176)



Discussion

Rate of postpartum glucose intolerance and metabolic syndrome is high in GDM women with high pre-pregnancy BMI. Early postpartum screening for metabolic syndrome must be a priority as well as glucose status in women with gestational diabetes particularly those who start pregnancy with excess body mass index.

1. Hansen, T.S., et al., 2014. Fasting insulin levels of an abdominal circumference in women with gestational diabetes. *Journal of Obstetrics, Gynecology & Neonatal Nursing*, 2014, 43(1): p. 53-57.

2. Shabazz, S.P., et al., 2014. History of gestational diabetes mellitus and future risk of atherosclerosis in mid-life: the Coronary Artery Risk Development in Young Adults Study. *Journal of the American Heart Association*, 2014, 3(2): p. e00444.

3. Dunstan, G., M.P. De Zeeuw, and S.E. Casanueva, Obesity or diabetes: Concomitance or the association between body mass index and postpartum obesity. *Int J Weight Control*, 2011, 2(2): p. 563-74.



Evaluation of the Protective Effects of Quercetin Against Methimazole-Induced Hepatotoxicity in Mice



Heibatulah Kalantari¹, **Bita Baratvand^{2*}**, Azin Samimi¹, Layasadat Khorsandi³

¹Department of Toxicology, School of Pharmacy, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.

²Pharm.D student, School of Pharmacy, Ahvaz Jundishapur University of medical sciences, Ahvaz, Iran.

³Department of Histology, School of Medicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.

Email: bbaratvand@gmail.com

Introduction

Liver is the organ that plays the most important role in body's physiology and maintaining metabolic homeostasis of the body [1]. Methimazole (MMI) is the most prescribed drug for managing hyperthyroidism in humans. However, hepatotoxicity is a deleterious side effect associated with MMI administration [2]. Quercetin is one of the most important bioflavonoids present in plants which is known for its multiple pharmacological activities [3]. The present study was designed to evaluate the possible hepatoprotective effects of quercetin, against methimazole-induced hepatotoxicity in mice.

Methods

Thirty five mice were randomly divided into five groups (7mice in each group), group one received normal saline as control group, group two received MMI (100 mg/kg i.p), and groups 3-5 received (70, 140 and 280 mg/kg i.p) Quercetin respectively + MMI for 5 days. On the fifth day, all groups received hexobarbital sodium (25 mg/kg, i.p) and sleeping time of all mice was recorded. After 24 hours mice were sacrificed. Serum and tissue biomarkers such as alanine aminotransferase (ALT), aspartate aminotransferase (AST), reduced glutathione (GSH), malondialdehyde (MDA) and histopathological studies eval-

Results and Discussion

The present study revealed that MMI (100mg/kg) Produced significant elevations in ALT, AST. Increased level of aminotransferases showed that the integrity of hepatocytes was abnormal in MMI alone treated mice. Administration of Quercetin prevented MMI-induced elevations of ALT and AST as compared to MMI alone treated group (figure1 and 2).




Figure 1: Effect of treatment with Quercetin on serum ALT level




Figure 2: Effect of treatment with Quercetin on serum AST level




Figure 3: Alterations in reduced glutathione (GSH) content




Figure 4: Alterations in lipid peroxidation activity

Histopathological investigations demonstrated that MMI-induced various changes such as inflammation in hepatocytes which confirmed the biochemical data. Treatment with Quercetin obviously mitigated the histopathological changes induced by MMI (figure 5). Histopathological findings supported the biochemical results.

We also observe a remarkable decrease in the level of GSH in MMI group animals compared to control group.

Reduction in glutathione reservoirs in hepatocytes treated with MMI, indicates that GSH has a critical role in detoxifying MMI metabolites and preventing cellular damage (figure 3).

Lipid peroxidation of unsaturated fatty acids is a commonly used index of increased oxidative stress and subsequent cytotoxicity [4]. We observed a significant increase in the concentration of MDA in liver of MMI alone treated mice. However, Pretreatment of mice with Quercetin prevented the MMI-induced increase in MDA as Compared to MMI group (figure 4).

The results showed that MMI significantly increased sleeping time, ALT, AST and MDA level and decreased GSH level when compared with control group (p<0.05). Pretreatment with Quercetin in all doses, prevented MMI-induced alterations in serum aminotransferases and MDA, as well as glutathione (p<0.05).




Figure 5: Histopathological evaluation of MMI toxicity in mice liver. (A) Control group, (B) treated with 100mg/kg MMI, (C, D, E) treated with 70mg/kg, 140mg/kg, 280mg/kg respectively along with 100mg/kg MMI. H&E Stain. F: fat deposit, C: congestion of RBCs, I: infiltration of inflammatory cells, P: pyknotic

Conclusion

In conclusion, our data indicate that quercetin exhibited hepatoprotective activity against methimazole-induced hepatotoxicity possibly through its antioxidant activity and effective in structural improvement of liver.

Keywords

Hepatotoxicity, Methimazole, Quercetin, Mice

1. Heibat H, Barakat H, Jundishapur U, Toghiani M, Olfendy M. Evaluation of the protective effects of quercetin against methimazole-induced hepatotoxicity in mice. *Journal of Pharmaceutical Sciences*. 2014; 1(1):1-5.
 2. Heibat H, Barakat H, Jundishapur U, Toghiani M, Olfendy M. Evaluation of the protective effects of quercetin against methimazole-induced hepatotoxicity in mice. *Journal of Pharmaceutical Sciences*. 2014; 1(1):1-5.
 3. Heibat H, Barakat H, Jundishapur U, Toghiani M, Olfendy M. Evaluation of the protective effects of quercetin against methimazole-induced hepatotoxicity in mice. *Journal of Pharmaceutical Sciences*. 2014; 1(1):1-5.
 4. Heibat H, Barakat H, Jundishapur U, Toghiani M, Olfendy M. Evaluation of the protective effects of quercetin against methimazole-induced hepatotoxicity in mice. *Journal of Pharmaceutical Sciences*. 2014; 1(1):1-5.

P-0966 Pharmacological intervention and postpartum metabolic outcomes in women with gestational diabetes

N. Ghodrati¹, S. Noudjahi¹, H. Shabbazi¹, B. Cheraghian¹, N. Shabbazi¹, S. Jahanshahi¹, A. Jahanshahi¹,
¹Faculty of Pharmacy- Student Research Committee- Ahvaz Jundishapur University of Medical Sciences- Ahvaz- Iran,
²Social determinants of Health Research Center- Ahvaz Jundishapur University of Medical Sciences- Ahvaz- Iran,
³Diabetes Research Center- Health Research Institute- Ahvaz Jundishapur University of Medical Sciences- Ahvaz- Iran,
⁴Department of Epidemiology and Biostatistics- Faculty of Health- Ahvaz Jundishapur University of Medical Sciences- Ahvaz- Iran,
⁵Department of Obstetrics and Gynecology- Imam Khomeini Hospital- Ahvaz Jundishapur University of Medical Sciences- Ahvaz- Iran,
⁶School of Health Sciences Building 2212- Room 2219 Central Michigan University- Mount Pleasant- MI 48859 - Michigan- USA.



Background

Need for treatment with insulin or metformin in pregnancy as an indicator of severity of hyperglycemia may reflect impairment in β -cell function in women exposed to gestational diabetes[1]. β -cell impairment has been associated with severity of MetS in adults[2].

Aim

We set out to determine the rate of glucose intolerance and metabolic syndrome at 6-12 weeks postpartum in women with gestational diabetes those requiring insulin or metformin for management of hyperglycemia.

Method

In this ongoing population-based prospective cohort study 176 women with GDM pregnancy underwent a fasting glucose test, 75-g oral glucose tolerance and fasting lipid tests at 6-12 weeks postpartum. GDM was defined based on International Association of Diabetes and Pregnancy Study Groups (IADPSG) criteria. Postpartum glucose intolerance was defined according to ADA criteria and metabolic syndrome using 2 sets of criteria, National Cholesterol Education Program Adult Treatment Panel (NCEP ATP III) and International Diabetes Federation (IDF) criteria.





Figure 1. Distribution of delivery and GDM in 8 area of Ahvaz city.

Results

Of 176 women with gestational diabetes 34 women (19.3%) required insulin or metformin for control of hyperglycemia in pregnancy.

Figure 2. Distribution of treatment of hyperglycemia in pregnancy



Mean age of drug users was 31.0 (SD, 4.67) years. Rate of postpartum glucose intolerance in women who were treated with insulin was 54.4% versus 41.7% in women who had taken metformin while the same rate was 15.4% in diet-only group. Pharmacotherapy for management of hyperglycemia in pregnancy was strong predictor of progression to abnormal glucose tolerance at 6-12 weeks postpartum (OR 3.14; 95% CI: 1.20- 8.21).

Rate of metabolic syndrome at 6-12 weeks postpartum in women who need pharmacotherapy for control of hyperglycemia was 35.3% in insulin or metformin users by NCEP-ATP III criteria (vs 14.1% in women treated with diet only) and 41.2% by IDF criteria (vs 16.2% in women treated with diet only). Requiring insulin or metformin for treatment of hyperglycemia in pregnancy was associated risk factors for the presence of MetS in GDM-exposed women (OR 3.08, 95% CI: 1.25-7.60, P=0.01).

Characteristic	Mean (SD)
Age (years)	31.0 (4.67)
Parity (0/1/2/3)	1.0 (0.31)
Parity (0/1/2/3)	1.0 (0.31)
Weight (kg)	65.0 (12.5)
Height (cm)	160.0 (5.5)
BMI (kg/m ²)	25.0 (3.5)
Waist circumference (cm)	85.0 (10.0)
Waist-hip ratio	0.85 (0.05)
SBP (mmHg)	110.0 (12.0)
DBP (mmHg)	70.0 (8.0)
Fasting glucose (mg/dL)	100.0 (15.0)
2-hour OGTT (mg/dL)	160.0 (30.0)

Table 1. Mean (SD) of Demographic, Clinical and Biochemical characteristics of women with gestational diabetes (diagnosed by IADPSG criteria)

Table 2. Distribution of metabolic syndrome and its components, in women with gestational diabetes in accordance with NCEP-ATP III and IDF criteria 6-12 weeks postpartum based on kind of hyperglycemia treatment in pregnancy

Characteristic	No. (%)	Demographic, Clinical or Biochemical (n=176)	P
Metabolic syndrome (NCEP)	35 (19.9)	14.1%	0.001
Metabolic syndrome (IDF)	41 (23.3)	16.2%	0.001
Insulin resistance	44 (25.0)	17.6%	0.001
High blood pressure	32 (18.2)	12.9%	0.001
High triglyceride	32 (18.2)	12.9%	0.001
Low HDL cholesterol	32 (18.2)	12.9%	0.001
High fasting glucose	32 (18.2)	12.9%	0.001
High 2-hour OGTT	32 (18.2)	12.9%	0.001

Discussion

Rate of postpartum glucose intolerance and metabolic syndrome is high in GDM women particularly in women who were treated with insulin or metformin (about 2.5-fold higher rate compared with diet-treated women). Early postpartum screening for metabolic syndrome must be a priority as well as glucose status in women with gestational diabetes those required pharmacotherapy in pregnancy.

**OUR RIGHT TO
A HEALTHY
FUTURE**



1. Kim, C., Maternal outcomes and follow-up after gestational diabetes mellitus. *Diabetic medicine: a journal of the British Diabetic Association*, 2014. 31(7): p. 292-301
 2. Malin, S.K., et al., β -Cell Dysfunction Is Associated with Metabolic Syndrome Severity in Adults. *Metabolic Syndrome and Related Disorders*, 2014. 12(2): p. 79-85.

Scientific poster 9

1396



بررسی اثرات درمان دستی بر فضای واگهای مراجعین خانم مبتلا به بدآوایی ناشی از تنش عضلانی



راهبیه زارع مهرچرمدی^{۱*}، دکترنگین مرادی^۱، دکتر محمد جعفر شاطرزاده^۲، دکتر مجید سلطانی^۱، احسان نادری فرز^۳،
دکتر مریم دستورپور^۲

۱- مرکز تحقیقات عصبی عضلانی، دپارتمان گفتاردرمانی، دانشگاه علوم پزشکی جندی شاپور اهواز، اهواز، ایران
۲- مرکز تحقیقات عصبی عضلانی، دپارتمان فیزیوتراپی، دانشگاه علوم پزشکی جندی شاپور اهواز، اهواز، ایران
۳- مرکز تحقیقات آلودگی هوا و بیماری‌های تنفسی، دانشگاه جندی شاپور اهواز اهواز، اهواز، ایران

ایمیل: s.najafi@pb.ac.ir

مقدمه:

بدآوایی ناشی از تنش عضلانی یک اختلال صدای رایج است که اغلب در بیمارانی با شل‌های استرس‌زا و تقاضاهای زیاد روی استفاده از صوتشان دیده می‌شود. این اختلال توسط تنش بیش از حد در عضلات پارافارینژیال و سوپراهایپوید، چپک خلفی باز، بالا رفتن حنجره و تغییرات مکرر موزونی روی تارهای صوتی مشخص می‌شوند. درمان دستی یکی از درمان‌های مورد استفاده برای دیسفونی ناشی از تنش عضلانی است (۱). در روش درمان دستی حنجره هدف این است که با کاهش تنش عضلات خارجی و اصلاح جایگاه حنجره، ویژگی‌های پارامترهای صوتی تغییر یابد و کیفیت صدا بهتر شود (۲). تاکنون اثرات فوری درمان دستی ثابت شده است ولی هدف در این مطالعه به تأثیر یک دوره صوت درمانی با روش درمانی دستی بر فضای واگهای در مراجعین مبتلا به دیسفونی ناشی از تنش عضلانی پرداخته شد.

مواد و روش‌ها:


در این مطالعه ۴ زن مبتلا به دیسفونی ناشی از تنش عضلانی طی هشت جلسه با استفاده از روش Ray تحت درمان قرار گرفتند. صدای نمونه‌ها قبل و بعد از جلسات درمانی اول و هشتم ضبط شد و با استفاده از نرم‌افزار PHAT تحلیل شد و فرمانت اول و دوم چهار واگهی (F1، F2، F3، F4) استخراج گردید. سپس با استفاده از فرمول:

$$0.5 \times ((F2_c \times F1_{pre} + F2_{pre} \times F1_c) + (F2_c \times F1_{post} + F2_{post} \times F1_c) + (F2_c \times F1_{pre} - F1_c) \times (F2_{pre} \times F1_{post} + F1_{pre} \times F2_{post} + F1_{pre} \times F2_{pre} + F1_{post} \times F2_{post}))$$

فضای واگهای قبل و بعد از درمان محاسبه شد. برای تجزیه و تحلیل داده‌ها از نرم‌افزار SPSS نسخه ۲۲ و از آزمون تی زوجی استفاده شد.

نتایج:

میانگین نمرات فضای واگهای برای جلسه اول و هشتم به ترتیب ۷۱۷۷۶ و ۲۰۸۳۳۳۳.۲، انحراف معیار به ترتیب ۲۱۵۰۲ و ۱۳۳۳۳۳ بود. میانگین فضای واگهای بعد از درمان به طور معناداری بیشتر از قبل از درمان بود (P-value < ۰۰۰۰۰۰۰۰).






بحث و نتیجه‌گیری:


اگرچه درمان دستی روی تولید تمرکز نمی‌کند ولی بهبود در آکوستیک‌های تولیدی مشاهده شده است. افراد مبتلا به دیسفونی ناشی از تنش عضلانی به صورت همزمان تنش عضلانی حنجره‌ای و تولیدی را تجربه می‌کنند که به نظر می‌رسد که با استفاده از درمان دستی بهبود می‌یابند. به نظر می‌رسد تغییرات فضای واگه ای به دنبال درمان، ناشی از ارتباطات بیومکانیکی بین فک پایین، زبان، حنجره و عضلات حلقی باشد. تغییرات در فرمانت‌ها می‌تواند به ریشه‌ی زبان، ارتفاع حنجره، پوزیشن قدامی-خلفی حایپوید، عضلات حلقی تحتانی یا ترکیبی از این‌ها نسبت داده شود. قبل از درمان سفنی حنجره می‌تواند در کوتاه شدن عضلات پری‌لارینژیال و کاهش انعطاف‌پذیری حرکات حایپوید شرکت کند. که اینها می‌توانند باعث کاهش آزادی حرکات زبان و فک بشوند. اگرچه دیسفونی ناشی از تنش عضلانی اختلالی صوت در نظر گرفته می‌شود. درمان آن با درمان دستی اثرات مثبتی روی سیستم تولیدی و آواسازی دارد.

Reference:

- Hoffman H, Karnell M. Common Voice Disorders: A Primary Care Approach. NCVS Status and Progress Report. 1994;7:187-96.
- Morrison MD, Rammage LA, Belisle GM, Pullan CB, Nichol H. Muscular tension dysphonia. J. of otolaryngology. 1983;12(5):302-6.
- Roy N, Nissen SL, Dromei C, Sapir S. Articulatory changes in muscle tenelon dysphonia: Evidence of vowel space expansion following manual circumlaryngeal therapy. Journal of communication disorders. 2009;42(2):124-35.







link:

<http://graphdan.ir/sample/animation/>

1396

scientific animations



@graphdanir



09013767627



www.Graphdan.ir